T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives
Type 1 diabetes (T1D) is an autoimmune disease driven by the activation of lymphocytes against pancreatic β-cells. Among β-cell autoantigens, preproinsulin has been ascribed a key role in the T1D process. The successive steps that control the activation of autoreactive lymphocytes have been extensiv...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2011/513210 |
id |
doaj-f479fd34b50d484b9207c1b9b63a0072 |
---|---|
record_format |
Article |
spelling |
doaj-f479fd34b50d484b9207c1b9b63a00722020-11-25T00:59:15ZengHindawi LimitedClinical and Developmental Immunology1740-25221740-25302011-01-01201110.1155/2011/513210513210T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical PerspectivesRoberto Mallone0Vedran Brezar1Christian Boitard2INSERM, U986, Hôpital St Vincent de Paul, 82 avenue Denfert Rochereau, 75014 Paris, FranceINSERM, U986, Hôpital St Vincent de Paul, 82 avenue Denfert Rochereau, 75014 Paris, FranceINSERM, U986, Hôpital St Vincent de Paul, 82 avenue Denfert Rochereau, 75014 Paris, FranceType 1 diabetes (T1D) is an autoimmune disease driven by the activation of lymphocytes against pancreatic β-cells. Among β-cell autoantigens, preproinsulin has been ascribed a key role in the T1D process. The successive steps that control the activation of autoreactive lymphocytes have been extensively studied in animal models of T1D, but remains ill defined in man. In man, T lymphocytes, especially CD8+ T cells, are predominant within insulitis. Developing T-cell assays in diabetes autoimmunity is, thus, a major challenge. It is expected to help defining autoantigens and epitopes that drive the disease process, to pinpoint key functional features of epitope-specific T lymphocytes along the natural history of diabetes and to pave the way towards therapeutic strategies to induce immune tolerance to β-cells. New T-cell technologies will allow defining autoreactive T-cell differentiation programs and characterizing autoimmune responses in comparison with physiologically appropriate immune responses. This may prove instrumental in the discovery of immune correlates of efficacy in clinical trials.http://dx.doi.org/10.1155/2011/513210 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Roberto Mallone Vedran Brezar Christian Boitard |
spellingShingle |
Roberto Mallone Vedran Brezar Christian Boitard T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives Clinical and Developmental Immunology |
author_facet |
Roberto Mallone Vedran Brezar Christian Boitard |
author_sort |
Roberto Mallone |
title |
T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives |
title_short |
T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives |
title_full |
T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives |
title_fullStr |
T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives |
title_full_unstemmed |
T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives |
title_sort |
t cell recognition of autoantigens in human type 1 diabetes: clinical perspectives |
publisher |
Hindawi Limited |
series |
Clinical and Developmental Immunology |
issn |
1740-2522 1740-2530 |
publishDate |
2011-01-01 |
description |
Type 1 diabetes (T1D) is an autoimmune disease driven by the activation of lymphocytes against pancreatic β-cells. Among β-cell autoantigens, preproinsulin has been ascribed a key role in the T1D process. The successive steps that control the activation of autoreactive lymphocytes have been extensively studied in animal models of T1D, but remains ill defined in man. In man, T lymphocytes, especially CD8+ T cells, are predominant within insulitis. Developing T-cell assays in diabetes autoimmunity is, thus, a major challenge. It is expected to help defining autoantigens and epitopes that drive the disease process, to pinpoint key functional features of epitope-specific T lymphocytes along the natural history of diabetes and to pave the way towards therapeutic strategies to induce immune tolerance to β-cells. New T-cell technologies will allow defining autoreactive T-cell differentiation programs and characterizing autoimmune responses in comparison with physiologically appropriate immune responses. This may prove instrumental in the discovery of immune correlates of efficacy in clinical trials. |
url |
http://dx.doi.org/10.1155/2011/513210 |
work_keys_str_mv |
AT robertomallone tcellrecognitionofautoantigensinhumantype1diabetesclinicalperspectives AT vedranbrezar tcellrecognitionofautoantigensinhumantype1diabetesclinicalperspectives AT christianboitard tcellrecognitionofautoantigensinhumantype1diabetesclinicalperspectives |
_version_ |
1725218353801330688 |